Day: September 12, 2016

Barfresh Products to be offered at Wegmans’ Restaurant Concept The Pub

BEVERLY HILLS, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) — Barfresh Food Group, Inc. (OTCQB:BRFH), a manufacturer of frozen, ready-to-blend beverages, is announcing a roll out within Wegmans Food Markets’ in-store restaurant concept The Pub.  Wegmans is consistently recognized as one of the premier supermarkets in the country and an innovator in food retailing with 90 locations throughout the Northeast.  The company currently operates 11 of its The Pub in-store restaurants with another opening soon.  Riccardo Delle Coste, Barfresh’s CEO stated, “Wegmans’ decades-long reputation as a leader in food retailing and customer engagement is unparalleled and we are honored to have

Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant

MADISON, Wis., Sept. 12, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces that its lead therapeutic compound, CLR 131, currently in a Phase 1 clinical trial for multiple myeloma and preparing for a Phase 2 study in multiple myeloma and other hematologic malignancies, will be evaluated by the University of Wisconsin in combination with external beam radiation as a potential combination treatment for head and neck cancers (squamous cell carcinoma).  The research will be conducted as part of a Specialized Program of Research Excellence (SPORE) grant, awarded to the University of Wisconsin

Buy-Side Firms Prioritize Liquidity and Relationships as Top Concerns in Broker Selection Process, According to TABB Group Study 

NEW YORK and LONDON, Sept. 12, 2016 (GLOBE NEWSWIRE) — The regulatory challenges and cost pressures facing buy-side firms are putting further demands on the sell-side to prove their relationship value. According to conversations with 100 U.S. head traders for the final installment of TABB Group’s 12th annual benchmark study, “Broker Relationships in an Era of Full Disclosure: U.S. Institutional Equity Trading 2016,” on why certain brokers were winning their order flow, 65% of the buy-side mentioned liquidity and 48% mentioned the broker relationship, while just 34% said non-execution services. Compared to 2015 overall, more buy-side firms mentioned liquidity and

Feature Box

Inovalon and MDLIVE Bring Real-Time Advanced Analytics to Telemedicine Marketplace

BOWIE, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) — Inovalon (NASDAQ:INOV), a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced a multi-year agreement with MDLIVE, a leading telehealth platform provider, to provide on-demand, real-time patient insights and analytics. The new capability will enable MDLIVE and its clients (health systems, ACOs, health plans and employers) to identify and close gaps in care as part of telehealth patient consultations as well as facilitate quality score and risk adjustment accuracy improvement across a wide variety of health plan, health system and employer populations. As part

PDC Energy Announces Full Exercise of Over-Allotment Options in Common Stock and Convertible Senior Notes Offerings

DENVER, Sept. 12, 2016 (GLOBE NEWSWIRE) — PDC Energy, Inc. (“PDC” or the “Company”) (Nasdaq:PDCE) today announced the underwriters in its recent public offerings of common stock (the “common stock offering”) and convertible senior notes (the “notes offering”) exercised their over-allotment option to purchase an additional (i) 1,185,000 shares of common stock in the case of the common stock offering, bringing the total shares to be purchased in that offering to 9,085,000, and (ii) an additional $25 million principal amount of additional notes in the case of the notes offering, bringing the total aggregate principal amount of that offering to

American Airlines Group Reports August Traffic

FORT WORTH, Texas, Sept. 12, 2016 (GLOBE NEWSWIRE) — American Airlines Group (NASDAQ:AAL) today reported August and year-to-date 2016 traffic results. American Airlines Group’s total revenue passenger miles (RPMs) were 20.4 billion, down 2.8 percent versus August 2015. Total capacity was 24.7 billion available seat miles (ASMs), up 1.4 percent versus August 2015. Total passenger load factor was 82.9 percent, down 3.6 percentage points versus August 2015. The Company continues to expect its third quarter 2016 total revenue per available seat mile to be down approximately 3.0 to 5.0 percent year-over-year. In addition, the Company continues to expect its third

TOMI™ Upgrades to the OTCQX® Best Market

– Shares will continue trading under the “TOMZ” symbol – BEVERLY HILLS, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) — TOMI™ Environmental Solutions, Inc. (TOMI) (OTCQX:TOMZ), a global bacteria decontamination and infection prevention company, announced its shares have begun trading on the OTCQX® Best Market. The company’s shares will continue trading under the symbol “TOMZ.” The OTCQX Best Market is designed for established, investor-focused U.S. and international companies that consistently meet financial and disclosure standards and are sponsored by a professional third-party advisor. Dr. Halden Shane, TOMI’s Chief Executive Officer, stated: “Upgrading our shares to the OTCQX is a significant achievement

Celsion Corporation Announces Independent NIH Analysis Showing Treatment with ThermoDox® Plus RFA May Significantly Improve Overall Survival of Patients with Primary Liver Cancer

Conclusions Drawn from Results of Celsion’s HEAT Study Prompted NIH Analysis; Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit Compared to Treatment with RFA Alone Abstract Accepted for Oral Presentation at the 2016 RSNA Annual Meeting LAWRENCEVILLE, N.J., Sept. 12, 2016 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ:CLSN) today announced that the National Institutes of Health (NIH) has conducted an independent retrospective analysis of data from the intent-to-treat population of the Company’s HEAT Study, a 701-patient study investigating ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radiofrequency ablation (RFA) in primary liver cancer, also

Aptose Submits Formal Response to Clinical Hold for APTO-253

SAN DIEGO and TORONTO, Sept. 12, 2016 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, announced today that it has submitted a formal response to the U.S. Food and Drug Administration (FDA) regarding the previously announced clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers.  Aptose provided responses to all of the questions cited in the clinical hold letter issued by the FDA. “This submission represents months of disciplined labor to resolve a manufacturing matter related to APTO-253

Inovio’s Zika Vaccine Selected As 2016 Technology Breakthrough

PLYMOUTH MEETING, Pa., Sept. 12, 2016 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its Zika vaccine in development has been named a 2016 Technology Breakthrough by the editors of Popular Mechanics magazine, the leading technology voice in the U.S. with millions of readers. Inovio has advanced its DNA-based Zika vaccine into two trials in the U.S., Canada and Puerto Rico. Inovio expects to have results before the end of this year for its U.S. study.  In addition, the CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential

Smart Card Alliance Highlights Significant Policy Considerations for Access Control in OMB Circular A-130 2016 Update

PRINCETON JUNCTION, N.J., Sept. 12, 2016 (GLOBE NEWSWIRE) — The Smart Card Alliance released today a paper in response to the 2016 update to the federal Office of Management and Budget (OMB) Circular A-130, “Managing Information as a Strategic Resource,” which defines federal policy and establishes guidance for management of federal information resources. In the response, the Smart Card Alliance highlights major changes in the policies governing federal use of PIV credentials for access control in the 2016 update to A-130, discusses the impact of these changes on the federal government and commercial industry, and outlines issues to be considered

TESARO Receives FDA Fast Track Designation for Niraparib and Initiates Rolling NDA Submission

WALTHAM, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to niraparib for the treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. TESARO has initiated a rolling submission of a New Drug Application (NDA) for niraparib to the FDA, and intends to complete this submission during the fourth quarter. The Marketing Authorization Application (MAA) for niraparib is planned for submission to the European Medicines Agency (EMA) in the fourth quarter. The FDA Fast Track designation

UniFirst Ranked No. 10 Best Company to Sell For

WILMINGTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE:UNF), an industry leader in the supply and servicing of uniforms, workwear, and ancillary facility products throughout the U.S. and Canada, has again secured a position in the top ten among Selling Power magazine’s annual list of 50 Best Companies to Sell For. The 2016 ranking continues UniFirst’s notable presence on the list, having first appeared in 2003, and marks UniFirst’s third year in a row finishing in the top ten. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/43828013-1d5a-4dde-96d0-a6f3cf5e0aad Each year, the corporate research team at Selling Power magazine

Global PVC Market set for rapid growth and expected to reach USD 78.90 Billion by 2021 – Zion Market Research

Sarasota, FL, Sept. 12, 2016 (GLOBE NEWSWIRE) — Zion Research has published a new report titled “PVC Market (Rigid PVC And Flexible PVC) by Application ( Pipes & Fittings, Wires & Cables, Films & Sheets, Bottles and Others) For Automotive, Electrical & Electronics, Construction, Packaging And Other End-User: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021”. According to the report, global demand for PVC Market was valued at USD 57.06 billion in 2015 and is expected to reach USD 78.90 billion in 2021, growing at a CAGR of 5.6% between 2016 and 2021. In terms

Karyopharm Appoints Humphrey A.R. Gardner MD, FCAP as Senior Vice President, Clinical Development

NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD, FCAP, as Senior Vice President, Clinical Development. Dr. Gardner will be responsible for clinical development planning and strategy, including building and leading clinical teams to achieve the Company’s long-term strategic objectives, and will report to Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of Karyopharm. “Dr. Gardner’s extensive clinical and industry experience will be invaluable to Karyopharm as we continue forward with advancing our lead, novel, oral Selective Inhibitor of Nuclear Export (SINE™) compound,

Rex Energy Provides Operational Update

STATE COLLEGE, Pa., Sept. 12, 2016 (GLOBE NEWSWIRE) — Rex Energy Corporation (Nasdaq:REXX) today provided an update on its Appalachian Basin operations. Operational Update Moraine East Area Joint Development Agreement The company’s joint development partner, Benefit Street Partners L.L.C. (“BSP”) has elected into the next four wells in the development program, the four-well Vaughn pad in the Warrior North Area. BSP’s election increases the total capital commitment to date by BSP from $98.1 million to $120.1 million. The company is currently drilling the second of four wells on the Vaughn pad and expects to place the four wells into sales

FTI Consulting Launches Geopolitical Intelligence Practice

WASHINGTON, Sept. 12, 2016 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE:FCN), the global business advisory firm dedicated to helping organizations protect and enhance their enterprise value, today announced the launch of its Geopolitical Intelligence practice. The practice, which includes professionals from the Company’s Forensic & Litigation Consulting and Strategic Communications segments, provides high-end political and policy analysis, bespoke consulting and corporate advisory solutions for a wide range of corporate and financial clients. “Companies are increasingly faced with the threat of unprecedented political risk and instability, impacting how they operate,” said Neal Hochberg, Global Leader of the Forensic & Litigation Consulting

Geron Provides Update on Imetelstat Trials Being Conducted by Janssen

MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq:GERN) today provided updates on the clinical trials being conducted by Janssen Research & Development, LLC, of the telomerase inhibitor imetelstat. Planned internal reviews of initial data from both trials have been completed by Janssen, and both trials are continuing in order to evaluate additional and more mature data. IMbarkTM IMbarkTM (NCT02426086) was originally designed as a Phase 2 clinical trial to evaluate two dose levels of imetelstat (either 4.7 mg/kg or 9.4 mg/kg administered every three weeks) in approximately 200 patients (approximately 100 patients per dosing arm) with

Takeda and MacroGenics Announce the Conclusion of their MGD010 License and Option Agreement

Rockville, MD, Sept. 12, 2016 (GLOBE NEWSWIRE) — and Osaka, Japan, Sept. 12, 2016 — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced the conclusion of their License and Option Agreement for MGD010. MacroGenics has regained the worldwide rights to MGD010, a bispecific molecule targeting CD32B and CD79B. Takeda’s decision comes earlier than the predefined expiration of its option exercise period and follows Takeda’s recently announced therapeutic area re-prioritization.

Solar Control Glass Market To Reach $8.88 Billion By 2024: Grand View Research, Inc.

San Francisco, Sept. 12, 2016 (GLOBE NEWSWIRE) — The global solar control glass market is expected to reach USD 8.88 billion by 2024, according to a new report by Grand View Research, Inc. Increasing demand owing to positive construction and automotive industry outlook is expected to propel solar control glass market growth. Solar control glass allows a significant amount of sunlight to pass through and reflects a large amount of solar heat thus making it suitable for green building applications. The growing trend of green buildings constructions with high energy efficiency and reduced CO2 emissions is expected to drive market demand